{
    "name": "testosterone topical",
    "comment": "Rx",
    "other_names": [
        "Androderm",
        "AndroGel",
        "Testim",
        "Axiron",
        "Fortesta",
        "Vogelxo"
    ],
    "classes": [
        "Androgens"
    ],
    "source": "https://reference.medscape.com/drug/androgel-testosterone-topical-342796",
    "pregnancy": {
        "common": [
            "Contraindicated in pregnant women; drug is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action; exposure of female fetus to metabolic-endocrine#androgens may result in varying degrees of virilization"
        ],
        "specific": [
            {
                "type": "Infertility",
                "description": [
                    "During treatment with large doses of exogenous metabolic-endocrine#androgens, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis; reduced fertility is observed in some men taking testosterone replacement therapy; testicular atrophy, subfertility, and infertility have been reported in men who abuse anabolic androgenic steroids; with either type of use, the impact on fertility may be irreversible"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring; these studies did not meet current standards for nonclinical development toxicity studies"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Drug is not indicated for use in women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Virilization can occur in children and women after secondary exposure to testosterone gel preparations",
                "Children and women should avoid contact with testosterone application sites on men using testosterone gel",
                "Testosterone gel users should adhere to recommended instructions for use"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Males with breast or prostate cancer",
                "Hypersensitivity",
                "Breast feeding women",
                "Pregnancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use with caution in patients with chronic lung disease, obesity, advanced age, or preexisting cardiac, renal, or hepatic disease",
                "Employ caution with prolonged use of high doses, which may be associated with hepatic effects",
                "May increase risk of prostate cancer",
                "Risk of gynecomastia when used for male hypogonadism",
                "May change serum lipid profile; use with caution in patients who have history of mycoardial infarction (MI) or coronary artery disease (CAD)",
                "Large doses may suppress spermatogenesis",
                "May increase hematocrit, which requires dose adjustment or discontinuation; monitor serum testosterone, prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit and hemoglobin periodically",
                "May cause hypercalcemia in patients with prolonged immolibization or cancer",
                "Anabolic activity of metabolic-endocrine#androgens may enhance hypoglycemia",
                "Children: Risks of inappropriate genital enlargement, premature pubic hair, advanced bone age, increased libido, and aggressive behavior",
                "Fortesta: Exogenous administration of metabolic-endocrine#androgens may lead to azoospermia; sleep apnea may occur in those with risk factors; preparation is flammable until dry",
                "Discontinue if urethral obstruction develops in patients with benign prostatic hyperplasia (BPH); monitor patients with BPH for worsening of signs and symptoms of BPH",
                "Edema with or without congestive heart failure, may be a complication in patients with pre-existing cardiac, renal, or hepatic disease; use with caution",
                "May worsen sleep apnea in some male patients",
                "Evaluate patients for cardiovascular risk factors prior to initiating therapy and monitor closely during therapy",
                "Use caution in patients with diseases that may be exacerbated by fluid retention, including cardiac, hepatic, or renal dysfunction; not recommended for men with poorly controlled heart failure",
                "Monitor women for virilization when treating for metastatic breast cancer",
                "Geriatric patients may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and increase in transaminase levels",
                "Increased hematocrit (polycythemia), reflective of increased red blood cell mass, may require discontinuation; increases risk for thromboemolism",
                "Venous thromboembolism, including DVT and PE reported in patients using testosterone products; these observations have included patients with and without polycythemia; evaluate signs or symptoms consistent with DVT or PE; if venous thromboembolic event suspected, discontinue treatment with testosterone and initiate appropriate workup and management",
                "Testosterone has been subject to abuse, typically at doses higher than recommended for approved indication and in combination with other anabolic androgenic steroids; anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions; if testosterone abuse suspected, check serum testosterone concentrations to ensure they are within therapeutic range; consider possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events",
                "Skin burns reported at application site in patients wearing an aluminized transdermal system during a magnetic resonance imaging scan (MRI); because transdermal testosterone patch contains aluminum, it is recommended to remove system before undergoing MRI"
            ],
            "specific": [
                {
                    "type": "Cardiovascular risks",
                    "description": [
                        "Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with the use of testosterone replacement therapy",
                        "January 31, 2014: FDA is investigating risk of stroke, MI, and death in men taking prescription testosterone drugs; investigation was prompted by findings from 2 studies suggesting increased risk of MI in men who take testosterone",
                        "In one study, analysis of 55,593 men with history of MI showed that men >65 years had 2-fold increase in MI risk within 90 days of filling initial prescription for testosterone drug; among younger men (<65 years) with history of heart disease, MI risk was increased 2- to 3-fold",
                        "This study confirmed results of earlier, much smaller study, which found that older men, many with underlying heart disease, had 30% increased chance of death, MI, and stroke after receiving testosterone therapy"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "testosterone topical increases effects of cyclosporine by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "testosterone topical will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "testosterone topical and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "testosterone topical, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of testosterone topical by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "testosterone topical will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "testosterone topical will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "testosterone topical increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "testosterone topical increases toxicity of carbamazepine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "testosterone topical will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "testosterone topical will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "testosterone topical increases effects of insulin degludec by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "testosterone topical increases effects of insulin degludec/insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "testosterone topical increases effects of insulin inhaled by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "testosterone topical increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "testosterone topical will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, testosterone topical.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "testosterone topical will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "testosterone topical will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acarbose",
            "description": {
                "common": "testosterone topical increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "androstenedione",
            "description": {
                "common": "androstenedione increases effects of testosterone topical by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "testosterone topical, budesonide.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "testosterone topical increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "testosterone topical, cortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "testosterone topical, deflazacort.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "testosterone topical, dexamethasone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epoetin alfa",
            "description": {
                "common": "testosterone topical increases effects of epoetin alfa by pharmacodynamic synergism. Minor/Significance Unknown. Androgens may be used to decrease necessary dose of epoetin alfa."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "testosterone topical, fludrocortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "testosterone topical increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "testosterone topical increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "testosterone topical increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "testosterone topical, hydrocortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "testosterone topical increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "testosterone topical increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "testosterone topical increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "testosterone topical increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "testosterone topical increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "testosterone topical increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "testosterone topical increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "testosterone topical increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "testosterone topical, methylprednisolone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miglitol",
            "description": {
                "common": "testosterone topical increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nateglinide",
            "description": {
                "common": "testosterone topical increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "testosterone topical increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "testosterone topical, prednisolone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "testosterone topical, prednisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "testosterone topical increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "testosterone topical increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "testosterone topical will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "testosterone topical will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto decreases effects of testosterone topical by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "testosterone topical increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "testosterone topical increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "testosterone topical increases effects of tacrolimus by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "testosterone topical increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "testosterone topical increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "testosterone topical, triamcinolone acetonide injectable suspension.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "testosterone topical increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pruritus at application site",
            "percent": "37"
        },
        {
            "name": "Skin reactions at application site",
            "percent": "16.1"
        },
        {
            "name": "Blisters under skin",
            "percent": "12"
        },
        {
            "name": "Erythema at application site",
            "percent": "7"
        },
        {
            "name": "Vesicles at application site",
            "percent": "6"
        },
        {
            "name": "Allergic contact dermatitis",
            "percent": "4"
        },
        {
            "name": "Burning at application site",
            "percent": "3"
        },
        {
            "name": "Induration at application site",
            "percent": "3"
        },
        {
            "name": "Abnormal dreams",
            "percent": null
        },
        {
            "name": "Acne",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Bladder irritability",
            "percent": null
        },
        {
            "name": "Breast soreness",
            "percent": null
        },
        {
            "name": "Cholestatic jaundice",
            "percent": null
        },
        {
            "name": "Deep vein thrombosis",
            "percent": null
        },
        {
            "name": "Dry skin",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Gynecomastia",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Menstrual irregularities",
            "percent": null
        },
        {
            "name": "Priapism",
            "percent": null
        },
        {
            "name": "Suppression of factors II",
            "percent": null
        },
        {
            "name": "V",
            "percent": null
        },
        {
            "name": "VII",
            "percent": null
        },
        {
            "name": "Virilization",
            "percent": null
        },
        {
            "name": "Vascular Disorders",
            "percent": null
        },
        {
            "name": "Venous thromboembolism",
            "percent": null
        },
        {
            "name": "Cardiovascular disorders",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "stroke",
            "percent": null
        },
        {
            "name": "Blood and lymphatic disorders",
            "percent": null
        },
        {
            "name": "Polycythemia",
            "percent": null
        }
    ]
}